drugset / Trial / NCT02577094
Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia
Phase 1/2
Withdrawn
Nantes University Hospital
Gilead Sciences · collabInstitut Cancerologie de l'Ouest · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Determination of the maximum tolerated dose (MTD) of fractionated RIT with epratuzumab radiolabeled with yttrium-90 (90Y-epratuzumab) preceding a reduced conditioning regimen FB2A2 before allogeneic stem cell transplantation.
Timeline
- Start
- —
- Primary completion
- 2017-01
- Completion
- 2017-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 90Y-DOTA-Epratuzumab | Unknown | — | Other |
| Background | Busulfan | Small molecule | — | — |
| Background | Epratuzumab | Monoclonal antibody | — | Other |
| Background | Fludarabine | Small molecule | — | — |
| Background | Thymoglobulines | Unknown | — | — |